The renin-angiotensin system (RAS) plays an integral role in cardiovascular homeostasis through its effects on vascular tone and volume, and pharmacologic interruption of this system has found widespread clinical application. Independent of effects of the RAS on blood pressure, activation of this system has been identified as a risk factor for the development of acute myocardial infarction (MI). It is hypothesized that activation of the RAS exerts a deleterious influence on fibrinolytic balance, and as such, reduces the activity of one of the major endogenous defense mechanisms against intravascular thrombosis. Vascular fibrinolytic balance is, to a large part, determined by the Competing effects of plasminogen activators and plasminogen activator inhibitor-1 (PAI-1), both of which are synthesized and secreted by the endothelium. This proposal is based on recent studies that establish the presence of a critical physiological relationship between the RAS and the fibrinolytic system. Preliminary data presented herein demonstrate that angiotensin: a) induces dose-dependent increases in endothelial PAI-1 production (mRNA and protein) in vitro; and b) selectively stimulates PAI- 1 secretion in vivo in humans. Moreover, recent studies performed in this laboratory confirm published reports that a novel form of receptor for angiotensin is present on endothelial cells, and provide the initial evidence that the hexapeptide angiotensin II (3-8), termed angiotensin IV (Ang IV) is the form of angiotensin that is responsible for the induction of endothelial PAI-1 production. These findings are particularly germane to our understanding of the mechanisms responsible for the newly- recognized anti-ischemic effects of ACE inhibitors, since elevated levels of PAI-1 constitute a risk factor for MI. This proposal is designed to examine endothelial cells as a target organ for angiotensin and to investigate the coordinated regulation of the RAS an endothelial fibrinolysis.
The specific aims of this proposal are the following: 1. To examine the effects of Ang IV on endothelial PAI-1 production and to characterize its mechanism of action; 2. To characterize the biochemical and molecular properties of the endothelial angiotensin receptor; and 3. To characterize the mechanisms through which ACE inhibitors enhance endothelial production of plasminogen activators. It is anticipated that these studies will generate critical new information regarding the interaction of the RAS, the vascular endothelium, and fibrinolysis. Furthermore, this project may contribute to our understanding of the regulation of two systems that play vital roles in cardiovascular homeostasis, and thus may improve our ability to prevent and treat ischemic cardiovascular disease.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Project (R01)
Project #
5R01HL051387-02
Application #
2228099
Study Section
Experimental Cardiovascular Sciences Study Section (ECS)
Project Start
1994-07-01
Project End
1998-05-31
Budget Start
1995-06-01
Budget End
1996-05-31
Support Year
2
Fiscal Year
1995
Total Cost
Indirect Cost
Name
Vanderbilt University Medical Center
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
004413456
City
Nashville
State
TN
Country
United States
Zip Code
37212
Vaughan, Douglas E; Rai, Rahul; Khan, Sadiya S et al. (2017) Plasminogen Activator Inhibitor-1 Is a Marker and a Mediator of Senescence. Arterioscler Thromb Vasc Biol 37:1446-1452
Afzal, Muhammad Zeeshan; Gartz, Melanie; Klyachko, Ekaterina A et al. (2017) Generation of human iPSCs from urine derived cells of patient with a novel heterozygous PAI-1 mutation. Stem Cell Res 18:41-44
Flevaris, Panagiotis; Khan, Sadiya S; Eren, Mesut et al. (2017) Plasminogen Activator Inhibitor Type I Controls Cardiomyocyte Transforming Growth Factor-? and Cardiac Fibrosis. Circulation 136:664-679
Rai, Rahul; Verma, Suresh K; Kim, David et al. (2017) A novel acetyltransferase p300 inhibitor ameliorates hypertension-associated cardio-renal fibrosis. Epigenetics 12:1004-1013
Yahata, Takashi; Ibrahim, Abd Aziz; Muguruma, Yukari et al. (2017) TGF-?-induced intracellular PAI-1 is responsible for retaining hematopoietic stem cells in the niche. Blood 130:2283-2294
Eren, Mesut; Place, Aaron T; Thomas, Paul M et al. (2017) PAI-1 is a critical regulator of FGF23 homeostasis. Sci Adv 3:e1603259
Rai, Rahul; Ghosh, Asish K; Eren, Mesut et al. (2017) Downregulation of the Apelinergic Axis Accelerates Aging, whereas Its Systemic Restoration Improves the Mammalian Healthspan. Cell Rep 21:1471-1480
Khan, Sadiya S; Shah, Sanjiv J; Klyachko, Ekaterina et al. (2017) A null mutation in SERPINE1 protects against biological aging in humans. Sci Adv 3:eaao1617
Afzal, Muhammad Zeeshan; Gartz, Melanie; Klyachko, Ekaterina A et al. (2017) Generation of human iPSCs from urine derived cells of a non-affected control subject. Stem Cell Res 18:33-36
Bautista-NiƱo, Paula K; Portilla-Fernandez, Eliana; Vaughan, Douglas E et al. (2016) DNA Damage: A Main Determinant of Vascular Aging. Int J Mol Sci 17:

Showing the most recent 10 out of 59 publications